Tags

Type your tag names separated by a space and hit enter

Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
Eur J Pharm Sci. 2013 Jul 16; 49(4):699-711.EJ

Abstract

Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer patients in comparison to conventional systemic chemotherapy. Inhalable particles are advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry powders containing paclitaxel were rationally designed via organic solution advanced spray drying (no water) in closed-mode from dilute concentration feed solution. Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. Scanning electron microscopy showed the spherical particle morphology of the inhalable particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state molecular order, and solid-state phase transition behavior. The residual water content of the particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel loaded into the particles was quantified which indicated high encapsulation efficiencies (43-99%). Dry powder aerosol dispersion performance was measured in vitro using the Next Generation Impactor (NGI) coupled with the Handihaler dry powder inhaler device and showed mass median aerodynamic diameters in the range of 3.4-7 μm. These results demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated phospholipid dry powder inhalation aerosol platform has great potential in lung cancer drug delivery.

Authors+Show Affiliations

University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences - Drug Development Division, Lexington, KY 40536-0596, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23707466

Citation

Meenach, Samantha A., et al. "Characterization and Aerosol Dispersion Performance of Advanced Spray-dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer." European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 49, no. 4, 2013, pp. 699-711.
Meenach SA, Anderson KW, Zach Hilt J, et al. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci. 2013;49(4):699-711.
Meenach, S. A., Anderson, K. W., Zach Hilt, J., McGarry, R. C., & Mansour, H. M. (2013). Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 49(4), 699-711. https://doi.org/10.1016/j.ejps.2013.05.012
Meenach SA, et al. Characterization and Aerosol Dispersion Performance of Advanced Spray-dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer. Eur J Pharm Sci. 2013 Jul 16;49(4):699-711. PubMed PMID: 23707466.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. AU - Meenach,Samantha A, AU - Anderson,Kimberly W, AU - Zach Hilt,J, AU - McGarry,Ronald C, AU - Mansour,Heidi M, Y1 - 2013/05/23/ PY - 2013/03/13/received PY - 2013/05/14/revised PY - 2013/05/15/accepted PY - 2013/5/28/entrez PY - 2013/5/28/pubmed PY - 2014/2/12/medline KW - Biocompatible biodegradable lipopolymers KW - Dry powder inhaler (DPI) KW - Lung surfactant KW - Nanomedicine KW - Nanotechnology KW - Respiratory drug delivery SP - 699 EP - 711 JF - European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences JO - Eur J Pharm Sci VL - 49 IS - 4 N2 - Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer patients in comparison to conventional systemic chemotherapy. Inhalable particles are advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry powders containing paclitaxel were rationally designed via organic solution advanced spray drying (no water) in closed-mode from dilute concentration feed solution. Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. Scanning electron microscopy showed the spherical particle morphology of the inhalable particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state molecular order, and solid-state phase transition behavior. The residual water content of the particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel loaded into the particles was quantified which indicated high encapsulation efficiencies (43-99%). Dry powder aerosol dispersion performance was measured in vitro using the Next Generation Impactor (NGI) coupled with the Handihaler dry powder inhaler device and showed mass median aerodynamic diameters in the range of 3.4-7 μm. These results demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated phospholipid dry powder inhalation aerosol platform has great potential in lung cancer drug delivery. SN - 1879-0720 UR - https://www.unboundmedicine.com/medline/citation/23707466/Characterization_and_aerosol_dispersion_performance_of_advanced_spray_dried_chemotherapeutic_PEGylated_phospholipid_particles_for_dry_powder_inhalation_delivery_in_lung_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0928-0987(13)00191-7 DB - PRIME DP - Unbound Medicine ER -